Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines

References

• Almirall J, Bolibar I, Vidal J, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 2000;15:757-63
   PubMed Web of Science ®Google Scholar
• Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993;137:977-88
   PubMed Web of Science ®Google Scholar
• Anderson RN. Deaths: leading causes for 2000. Natl Vital Stat Rep 2002;50:1-86
   PubMedGoogle Scholar
• Talwar A, Lee H, Fein A. Community-acquired pneumonia: what is relevant and what is not?. Curr Opin Pulm Med 2007;13:177-85
   PubMed Web of Science ®Google Scholar
• Grossman RF, Rotschafer JC, Tan JS. Antimicrobial treatment of lower respiratory tract infections in the hospital setting. Am J Med 2005;118(Suppl. 7A):29-38
   Google Scholar
• Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998;20:820-37
   PubMed Web of Science ®Google Scholar
• Lave JR, Lin CJ, Fine MJ, et al. The cost of treating patients with community-acquired pneumonia. Semin Respir Crit Care Med 1999;20:189-97
   Web of Science ®Google Scholar
• Aliyu ZY, Aliyu MH, McCormick K. Determinants for hospitalization in ‘low-risk’ community acquired pneumonia. BMC Infect Dis 2003;3:11
   PubMed Web of Science ®Google Scholar
• Talwar A, Lee H, Fein A. Community-acquired pneumonia: what is relevant and what is not?. Curr Opin Pulm Med 2007;13:177-85
   PubMed Web of Science ®Google Scholar
• Kuti JL, Capitano B, Nicolau DP. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. Pharmacoeconomics 2002;20:513-28
   PubMed Web of Science ®Google Scholar
• Blondeau J. A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J Antimicrob Chemother 1999;43:1-11
   PubMed Web of Science ®Google Scholar
• Miravittles M. Moxifloxacin in respiratory tract infections. Expert Opin Pharmacother 2005;6:283-93
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics: Avelox, INN moxifloxacin 400 mg. London: European Medicines Agency, 2002. Available at: www.emea.europa.eu/pdfs/human/referral/avelox/Avelox-Annex%20I-III-en.pdf [Last accessed 27 October 2008]
   Google Scholar
• Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138-80
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44 (Suppl. 2):S27-72
   PubMed Web of Science ®Google Scholar
• Cortoos PJ, De Witte K, Peetermans W, et al. Opposing expectations and suboptimal use of a local antibiotic hospital guideline: a qualitative study. J Antimicrob Chemother 2008;62:189-95
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Available at: http://www.nice.org.uk [Last accessed 3 July 2009]
   Google Scholar
• Drummond M, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 2005
   Google Scholar
• Welte T. Making the right choices for your CAP patient. Presentation at the Annual Congress of the European Respiratory Society. Berlin, 4-8 October 2008
   Google Scholar
• Martin M, Quilici S, File T, et al. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance. J Antimicrob Chemother 2007;59:977-89
   PubMed Web of Science ®Google Scholar
• Martin M, Moore L, Quilici S, et al. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium. Curr Med Res Opin 2008;24:737-51
   PubMed Web of Science ®Google Scholar
• Moore L, Martin M, Quilici S, et al. The cost-effectiveness of targeted prescribing of antimicrobials in Canada for community-acquired pneumonia in an era of antimicrobial resistance. Value Health 2008;11:A271-72
   Google Scholar
• Sabes-Figuera R, Segu JL, Puig-Junoy J, et al. Influence of bacterial resistances on the efficiency of antibiotic treatments for community-acquired pneumonia. Eur J Health Econ 2008;9:23-32
   PubMed Web of Science ®Google Scholar
• Torres A, Muir JF, Corris P, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J 2003;21:135-43
   PubMed Web of Science ®Google Scholar
• Petitpretz P, Arvis P, Marel M, et al. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001;119:185-95
   PubMed Web of Science ®Google Scholar
• Hoeffken G, Meyer HP, Winter J, et al. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001;95:553-64
   PubMed Web of Science ®Google Scholar
• Faich GA, Morganroth J, Whitehouse AB, et al. Clinical experience with moxifloxacin in patients with respiratory tract infections. Ann Pharmacother 2004;38:749-54
   PubMed Web of Science ®Google Scholar
• Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med 2004;98:708-20
   PubMed Web of Science ®Google Scholar
• Higuera F, Hidalgo H, Feris J, et al. Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1996;37:555-64
   PubMed Web of Science ®Google Scholar
• Mathers DL, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 2004;26:48-62
   PubMed Web of Science ®Google Scholar
• Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004;54:515-23
   PubMed Web of Science ®Google Scholar
• Gordon KA, Biedenbach DJ, Jones RN. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2003;46:285-9
   PubMed Web of Science ®Google Scholar
• Cabre M. Pneumonia in the elderly. Curr Opin Pulm Med 2009;15:223-9
   PubMed Web of Science ®Google Scholar
• Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005;330:456
   PubMed Web of Science ®Google Scholar
• Drummond MF, Becker DL, Hux M, et al. An economic evaluation of sequential IV/po moxifloxacin therapy compared to IV/po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 2003;124:526-35
   PubMed Web of Science ®Google Scholar
• Bauer TT, Welte T, Ernen C, et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 2005;128:2238-46
   PubMed Web of Science ®Google Scholar
• Lloyd A, Battleman D, Choudhri S, et al. Cost-effectiveness analysis of intravenous moxifloxacin compared to levofloxacin in hospitalized elderly patients with community-acquired pneumonia. Presentation at the 6th European Congress of Clinical Microbiology and Infectious Diseases. Nice, 1-4 April 2006
   Google Scholar
• Davis SL, Delgado G, McKinnon PS. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia. Clin Infect Dis 2005;41(Suppl. 2):136-43
   Google Scholar
• Robenshtok E, Shefet D, Gafter-Gvili A, et al. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database of Systematic Reviews, 2008, Issue 1. Art. No.: CD004418. DOI: 10.1002/14651858.CD004418.pub3
   Google Scholar
• Baxter R, Ray GT, Fireman BH. Case–control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 2008;29:44-50
   PubMed Web of Science ®Google Scholar
• Deshpande A, Pant C, Jain A, et al. Do fluoroquinolones predispose patients to Clostridium difficile associated disease?. A review of the evidence. Curr Med Res Opin 2008;24:329-33
   PubMed Web of Science ®Google Scholar
• Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter?. Semin Respir Crit Care Med 2009;30:210-38
   PubMed Web of Science ®Google Scholar
• Jones ME, Blosser-Middleton RS, Critchley IA, et al. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000–2001. Clin Microbiol Infect 2003;9:590-99
   PubMed Web of Science ®Google Scholar
• Valcke Y. CAP guidelines: why differences between Belgian and American/Canadian guidelines? Louvain: Université Catholique de Louvain, 2001. Available at: www.farm.ucl.ac.be/seminfec//Atelier-Mandell-23-11-01/Valcke/Valcke.pdf [Last accessed 25 February 2008]
   Google Scholar
• Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52:229-46
   PubMed Web of Science ®Google Scholar
• Green K, McGeer A, Plevneshi A, et al. on behalf of the Canadian Bacterial Surveillance Network. Trends in antimicrobial resistance in S. pneumoniae, Canada, 1993-2007. Presentation at the 18th European Congress of Clinical Microbiology and Infectious Diseases. Barcelona, 19 April 2008
   Google Scholar
• Goldstein F, Bryskier A, Appelbaum PC, et al. The etiology of respiratory tract infections and the antibacterial activity of fluoroquinolones and other oral antibacterial agents against respiratory pathogens. Clin Microbiol Infect 1998;4(Suppl. 2):S8-S18
   PubMedGoogle Scholar
• Simoens S, Verhaegen J, Laekeman G, et al. Treating respiratory tract infections in ambulatory care in Belgium: fluoroquinolone consumption and resistance development. Int J Antimicrob Agents 2005;26:62-8
   PubMed Web of Science ®Google Scholar
• Institut Pasteur. Evolution of fluoroquinolone resistance and detection of resistance mechanisms in clinical isolates of streptococcus pneumoniae collected in Belgium in 1995 – 2005. Brussels: Institut Pasteur, 2006. Available at: www.pasteur.be/pasteur_fr/index5930.html?page=antibiotic_research [Last accessed 21 October 2008]
   Google Scholar
• Low DE. Managing antibiotic resistance: resistance patterns and effects on practice. Canadian Bacterial Surveillance Network. Available at: http://microbiology.mtsinai.on.ca/research/cbsn/cbsnnews/cbsn2005_eng.pdf [Last accessed 29 October 2008]
   Google Scholar
• Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?. Clin Infect Dis 2005;41:139-48
   PubMed Web of Science ®Google Scholar
• Hoban D, Felmingham D. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J Antimicrob Chemother 2002;50(Suppl. S1):49-59
   PubMedGoogle Scholar
• Felmingham D, Reinert RR, Hirakata Y, et al. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 2002;50(Suppl. S1):25-37
   PubMedGoogle Scholar
• Torrance G, Walker V, Grossman R, et al. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. Pharmacoeconomics 1999;16:499-520
   PubMed Web of Science ®Google Scholar
• MacDougall C, Powell JP, Johnson CK, et al. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005;41(4):435-40
   PubMed Web of Science ®Google Scholar
• Ray GT, Baxter R, DeLorenze GN. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-non susceptible Pseudomonas aeruginosa. Clin Infect Dis 2005;41(4):441-9
   PubMed Web of Science ®Google Scholar